Skip links

Author: oncologs.com

antibody-reduces-allergic-reactions-to-multiple-foods-in-nih-trial

Antibody reduces allergic reactions to multiple foods in NIH trial

A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a late-stage clinical trial. Nearly 67% of participants who completed
gz17-6.02-with-bexarotene-kills-mycosis-fungoides-cells

GZ17-6.02 with bexarotene kills mycosis fungoides cells

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, mycosis fungoides.” Credit: 2024 Booth et al. “The present studies were performed to
for-faster-access-to-gene-and-cell-therapies-in-europe

For faster access to gene and cell therapies in Europe

Gene and cell therapies are among the most important innovations in the healthcare sector. And they reflect advances in science and technology. They have the potential to radically reshape the treatment of cancer, autoimmune diseases, neurodegenerative disorders, and many rare genetic conditions. But the path
a-very-long,-winding-road:-developing-novel-therapeutics-for-metastatic-tumors

A very long, winding road: Developing novel therapeutics for metastatic tumors

“Given that the MET inhibitor capmatinib caused a remarkable response in Dr. Blagosklonny, a pertinent question remains as to why he was not treated with ‘preemptive drug combinations’ […]” Credit: 2024 Dent. “Given that the MET inhibitor capmatinib caused a remarkable response in Dr. Blagosklonny,
Explore
Drag